Medizinische Universität Graz - Research portal
SHR
Neuro
Cancer
Cardio
Metab
Microb
Lipid
Nanomedicine for target-specific imaging and treatment of atherothrombosis : development and initial clinical feasibility
- Abstract
- NanoAthero is a European-funded project under the 7th Framework Programme for Research. The main objective of this project is to address more in depth prospects of improved diagnosis and treatment of atherosclerosis by means of nanotechnology.
Facts & Figures
- Total project volume: EUR 12.8 million
- Project time: five years (1026 person-months)
- Start of the project: 1 February 2013
- 16 partners from 10 countries
Objectives:
NanoAthero aims to demonstrate initial clinical feasibility of nanosystems for targeted imaging and treatment of advanced atherosclerotic disease in humans. The nanosystems are assemblies of following components: nanocarrier, targeting, imaging agent/drug. They have proven safety records, and strong preliminary in vitro and in vivo proofs of efficacy are available. Partners have patented and provided evidence of efficacy of carriers and ligands.
Over 5 years, NanoAthero will integrate GMP production, the initiation of clinical investigations in high-risk patients, including the preparation of regulatory dossiers, risk and ethical assessments, and the evaluation of the performance of optimized diagnostic and therapeutic compounds. NanoAthero offers a unique opportunity for combining in-depth knowledge of nanocarrier bioengineering and production with state-of the art expertise in imaging and treatment of cardiovascular patients providing a full bench-to-bedside framework within one collaborative consortium of 16 partners.
NanoAthero gathers together leading chemists, engineers, pharmacists, biologists, toxicologists, clinicians, analysts, ethicists and key-opinion leaders in the field of cardiovascular medicine and early drug development, a European association, 3 SMEs and a large pharmaceutical company (i.e.Bracco).
Phase I clinical trials targeting pivotal pathways in atherothrombosis will be performed with nanosystems for diagnosis and treatment of carotid atheroma and stroke. NanoAthero aims to complete phase I evaluation of two nanosystems: thrombus imaging and plaque stabilization in high-risk patients. Preclinical studies for two nanosystems (one to dissolve blood clots in stroke and one for plaque imaging) will be collaboratively completed and collection of clinical data will be launched.
- Keywords
- medical diagnostics
- Molecular pathology
- electrical and biomedical technics
- magnetic resonance tomography
- circulatory diseases
- laboratory diagnostics
- Biotechnology
- Atherosklerose
- Diagnostik
- Nanotechnologie
- Therapie
- Local Subprojectlead:
- Mangge Harald
- Duration:
- 01.02.2013-31.01.2018
- Programme:
- EU (FP-7)
- Subprogramme
- NMP.2012.1.2-2: Development and phase-I clinical trials of novel therapeutic nanotechnology-enabled systems for the diagnosis and treatment of atherosclerosis.
- EU-Project Instruments
- Collaborative Project (Large-Scale Integrating Project)
- Type of Research
- applied research
- Staff
- Mangge, Harald, Project Leader
- Pailer, Sabine, Co-worker
- Almer, Gunter, Co-worker
- Opriessnig, Peter, Co-worker
- MUG Research Units
- Clinical Institute of Medical and Chemical Laboratory Diagnostics
- Project partners
- Assistance Publique - Hopitaux de Paris, France
- Bracco Imaging SpA, Italy
- Commissariat a l´Energie Atomique et aux Energies Alternatives, France
- Edinethics, United Kingdom
- INSERM, France
- Inserm-Transfert, France
- Max-Planck-Society, Germany
- NanoPET Pharma, Germany
- Odense University Hospital, Denmark
- Semmelweis University Budapest, Hungary
- University of Erlangen, Germany
- University of Twente, Netherlands
- WizSoft, Israel
- , Netherlands